Metal- based nanoparticles as carriers of mTHPC drug for effective photodynamic therapy

Haimov, Elina; Harel, Yifat; Polani, Shlomi; Weitman, Hana; Zitoun, David; Lellouche, Jean‐Paul; Shefi, Orit

doi:10.1117/12.2508456

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently developed metal‐based nanoparticles have been incorporated as carriers for photosensitizer drug and are composed of either magnetically responsive carriers such as Yb‐doped or Ce‐doped maghemite NPs (MNPs) or gold as carriers and demonstrate stability and improved penetration into tissues such as cancer tissues …”

Section: Emerging Researches In Nanotechnology Related To Admentioning

confidence: 99%

Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives

Harilal

Jose

Parambi

et al. 2019

Journal of Pharmacy and Pharmacology

123

View full text Add to dashboard Cite

Objectives Considerable progress has been made in the treatment of Alzheimer's disease (AD), but all available strategies focus on alleviating symptoms rather than curing, which means that AD is viewed as an unresolvable neurodegenerative disease. Nanotechnological applications offer an alternative platform for the treatment of neurodegenerative diseases. This review aims to summarize the recent nanomedicine and nanotechnology developments for the treatment of AD. Key findings A plethora of nanocarriers and nanoparticle prodrugs have been reported to have negligible cytotoxicity in animal models, and these developments have revealed new opportunities for development of new classes of potent drug formulations for AD. Different nanotechnology-based approaches such as polymers, emulsions, lipo-carriers, solid lipid carriers, carbon nanotubes and metal-based carriers have been developed over the past decade, and they have been focusing on both neuroprotective and neurogenerative techniques to treat AD. Studies also reveal that nanotechnological approaches can aid in early diagnosis of AD and enhance therapeutic efficacy and bioavailability. Summary Notably, the drugs used conventionally to target the central nervous system have limitations that include an inability to cross the 'blood-brain barrier' or the 'blood-cerebrospinal fluid barrier' effectively and high drug efflux due to the activity of P-glycoprotein, but these limitations can be successfully overcome when nanocarriers are used for targeted drug delivery in AD.

show abstract

Section: Emerging Researches In Nanotechnology Related To Admentioning

confidence: 99%

Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives

Harilal

Jose

Parambi

et al. 2019

Journal of Pharmacy and Pharmacology

123

View full text Add to dashboard Cite

show abstract

Potential Neuroprotective Strategies using Smart Drug Delivery Systems for Alzheimer’s Disease

Khan,

Yadav,

Alam

2024

IDDT

View full text Add to dashboard Cite

Background: Alzheimer's disease (AD) is the most common neurological disorder, affecting more than 50 million individuals worldwide and causing gradual but progressive cognitive decline. The rising cost of medical treatment is mostly attributable to AD. There are now mainly a few slightly symptomatic therapeutic options accessible. Although this is not the primary reason, the failure to develop effective treatments for AD is often attributed to the disease's complicated pathophysiology and the wide range of underlying ideas. Objective: Studies undertaken over the past decade have aimed to find novel methods of overcoming these barriers and effectively delivering drugs to the central nervous system. As a result, nanotechnology provides a promising alternative to the standard means of administering anti-amyloidosis drugs, enhancing expectations for a successful treatment of Alzheimer's disease. These therapeutic implications of using nanoparticle-based approaches for the treatment of Alzheimer's disease are discussed in this paper. Methodology: Published articles from PubMed, SciFinder, Google Scholar, ClinicalTrials.org, and the Alzheimer Association reports were carefully examined to compile information on the various strategies for combating AD. That has been studied to summarize the recent advancements and clinical studies for the treatment of Alzheimer's disease (AD). Statistics is the study and manipulation of data, including ways to gather, review, analyze, and draw conclusions from data. Conclusion: The biology of the BBB and its processes of penetration must be carefully taken into account while creating DDSs. If we have a better grasp of the disease's mechanism, we might be able to overcome the shortcomings of current treatments for AD. Different DDSs show interesting properties for delivering medication tailored to the brain. This review paper examines the recent applications of DDSs in diverse domains. By selecting the best targeting vectors and optimizing the combination of carriers, multifunctionalized DDS may be produced, and these DDS have a significant impact on AD therapy potential. To develop DDSs with the best therapeutic efficacy and manageable side effects, experts from a variety of fields may need to contribute their efforts. Currently, the therapeutic use of nanotechnology-based DDSs appears to be a promising prospect for AD therapy, and as the pathophysiology of AD is better understood, this strategy will develop over time.

show abstract

Metal- based nanoparticles as carriers of mTHPC drug for effective photodynamic therapy

Cited by 2 publications

References 45 publications

Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives

Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives

Potential Neuroprotective Strategies using Smart Drug Delivery Systems for Alzheimer’s Disease

Contact Info

Product

Resources

About